Priority Income Fund Declares Cash Distributions For September Through November 2025

Priority Income Fund, Inc. ("Priority Income Fund" or the "Fund") announced today that the Fund's Board of Directors has declared monthly cash "base" and "bonus" common shareholder distributions for September 2025, October 2025 and November 2025. The distributions remain consistent with prior declared monthly distributions.

The annualized total cash distribution is $1.34016 per share (22.0% annualized rate based on the July 31, 2025 net asset value), for distributions with record dates between September 15, 2025 and November 4, 2025 based on the current net asset value of $6.09 per common share.

The cash "base" distribution will have monthly record dates and will be payable monthly to common stockholders of record at the close of business each month. These declared distributions equal a weekly cash amount of $0.02014 per share of common stock (or $0.26182 on a quarterly basis) as follows:

These distributions represent the 141st, 142nd, and 143rd consecutive monthly "base" distributions paid by the Fund.

The Fund's Board of Directors has also declared monthly cash "bonus" distributions, as follows:

The September, October and November cash "bonus" distributions represent the 60th, 61st, and 62nd monthly "bonus" distributions that the Fund has declared.

The Fund has paid or declared cumulative cash distributions totaling $16.73 per common share since inception in January 2014 through November 2025.

The Fund also announced the declaration of distributions on shares of the Fund's 7.00% Series D Term Preferred Stock due 2029 ("Series D"), 6.000% Series J Term Preferred Stock due 2028 ("Series J"), 7.000% Series K Cumulative Preferred Stock ("Series K"), and 6.375% Series L Term Preferred Stock due 2029 ("Series L").

Distributions shall first be treated as a distribution of taxable investment company income undistributed from the prior year, and then treated as a distribution of taxable investment company income for the current year. This treatment will not affect tax reporting to shareholders.